Fourth Estate Public Benefit Corporation

Morgan & DiSalvo, P.C. Recognized by Best Lawyers® as a 2024 Tier 1 Law Firm for "Trusts and Estates Law" in Georgia

Retrieved on: 
Thursday, November 2, 2023
P.C, Feedback, Organization, Fourth Estate Public Benefit Corporation, Morgan, DiSalvo, Lawyer, Trust law, Atlanta metropolitan area

ALPHARETTA, Ga., Nov. 2, 2023 /PRNewswire-PRWeb/ -- Morgan & DiSalvo, P.C. announced that the firm has received a Tier 1 ranking in Trusts & Estates Law by Best Lawyers®, representing the Greater Atlanta region for an impressive twelve years in a row.

Key Points: 
  • announced that the firm has received a Tier 1 ranking in Trusts & Estates Law by Best Lawyers®, representing the Greater Atlanta region for an impressive twelve years in a row.
  • "We are very appreciative to be recognized once again as a Tier 1 Law Firm for Trusts & Estates Law by one of the oldest rankings organizations in the legal profession."
  • The "Best Law Firms" rankings are based on a combination of client feedback, information provided from surveys, and peer reviews.
  • A Tier 1 designation indicates that a firm has earned a high level of respect from other leading lawyers and clients in their communities.

Veeva Introduces Study Portal and VeevaID to Streamline Research Site Trial Execution

Retrieved on: 
Wednesday, September 13, 2023
Fourth Estate Public Benefit Corporation, PBC, Professional corporation, Clinical trial, PT, Health, NYSE, Online shopping, Veeva Systems

PLEASANTON, Calif., Sept. 13, 2023 /PRNewswire/ -- 2023 Veeva R&D and Quality Summit, North America -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Portal, a free cloud application to simplify research site access to sponsor technologies. Study Portal will make it easy for clinical researchers to create and share study profiles containing links to all the relevant sponsor technology systems used for a clinical trial. Users will be able to securely store their individual usernames and passwords with the study profile rather than managing multiple links, usernames, and passwords on sticky notes or spreadsheets. Study Portal will work with all sponsor technology systems.

Key Points: 
  • PLEASANTON, Calif., Sept. 13, 2023 /PRNewswire/ -- 2023 Veeva R&D and Quality Summit, North America -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Portal , a free cloud application to simplify research site access to sponsor technologies.
  • Study Portal will make it easy for clinical researchers to create and share study profiles containing links to all the relevant sponsor technology systems used for a clinical trial.
  • In addition to Study Portal, Veeva announced VeevaID to provide single sign-on for clinical researchers across all sponsor systems, such as Veeva Vault EDC , Veeva Vault Study Training , and Veeva RTSM .
  • Veeva Study Portal and VeevaID are planned for availability in December 2023.

Veeva Introduces Study Portal and VeevaID to Streamline Research Site Trial Execution

Retrieved on: 
Wednesday, September 13, 2023
Fourth Estate Public Benefit Corporation, PBC, Professional corporation, Clinical trial, PT, Health, NYSE, Online shopping, Veeva Systems

BARCELONA, Spain, Sept. 13, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Portal, a free cloud application to simplify research site access to sponsor technologies. Study Portal will make it easy for clinical researchers to create and share study profiles containing links to all the relevant sponsor technology systems used for a clinical trial. Users will be able to securely store their individual usernames and passwords with the study profile rather than managing multiple links, usernames, and passwords on sticky notes or spreadsheets. Study Portal will work with all sponsor technology systems.

Key Points: 
  • BARCELONA, Spain, Sept. 13, 2023 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva Study Portal , a free cloud application to simplify research site access to sponsor technologies.
  • Study Portal will make it easy for clinical researchers to create and share study profiles containing links to all the relevant sponsor technology systems used for a clinical trial.
  • In addition to Study Portal, Veeva announced VeevaID to provide single sign-on for clinical researchers across all sponsor systems, such as Veeva Vault EDC , Veeva Vault Study Training , and Veeva RTSM .
  • Veeva Study Portal and VeevaID are planned for availability in December 2023.

MPOWER Financing Completes B Corporation™ Certification

Retrieved on: 
Tuesday, August 15, 2023
Good, Fourth Estate Public Benefit Corporation, Private sector, Social impact, B Lab, Ben, Education, PBC, Laureate Education, Mpower Financing, Shoe, Coursera, Professional corporation, American City Business Journals, Movement, Etsy, Certification, Student, Dream, UN, Corporation, Entrepreneurship, Ben & Jerry's, Environment, Management, Nursing

WASHINGTON, Aug. 15, 2023 /PRNewswire/ -- MPOWER Financing ("MPOWER"), a mission-driven fintech firm and a leading provider of scholarships and no-cosigner loans to promising students from around the world, announced today that it has completed a 2-year process to become a Certified B Corporation™ ("B Corp"), another key milestone in its long-term commitment to making a positive social impact on a global scale.

Key Points: 
  • Certified B Corps are leaders in the worldwide movement to drive an inclusive, equitable, and regenerative economy, according to B Lab , the nonprofit organization that verifies and credentials B Corp applicants.
  • B Lab performed a comprehensive review of MPOWER's social and environmental policies and processes across five categories: governance, workers, community, environment and customers.
  • "This certification is a testament to MPOWER's continued commitment to democratizing access to education for millions of promising students from around the world," said Manu Smadja, CEO and Co-Founder of MPOWER Financing.
  • The B certification comes on top of several other impact distinctions that MPOWER received this year, including being a Certified Great Place to Work, topping the Washington Business Journal's Corporate Diversity Index, and Fintech Futures Banking For Good.

PROSE, THE GLOBAL LEADER IN PERSONALIZATION, DEBUTS AI-POWERED SKINCARE

Retrieved on: 
Wednesday, June 28, 2023
Heart, Fourth Estate Public Benefit Corporation, Climate, Allantoin, Diet, Professional corporation, Genetically modified organism, Carbon, Hyaluronic acid, Science, Dermatology, Blue Light, Philosophy, Entrepreneurship, Growth, AI, 1998 Pep Boys 400K, Skin, Cosmetics, Prose

NEW YORK, June 28, 2023 /PRNewswire/ -- Today, Prose, the Brooklyn-based global leader in personalization, announces their expansion into skincare. The brand, known for delivering custom hair care designed for the individual, aims to offer an alternative to mass-produced skincare with their latest line: the only skincare system to offer truly personalized formulas, backed by science and powered by AI, that evolves with you over time.

Key Points: 
  • NEW YORK, June 28, 2023 /PRNewswire/ -- Today, Prose , the Brooklyn-based global leader in personalization, announces their expansion into skincare.
  • The skincare system not only includes bespoke formulas to suit each individual's skincare needs, but also offers texture and fragrance customization, including a fragrance-free option for those with sensitive skin.
  • After such incredible success with hair care, skincare was the next natural step for Prose to continue as a leader in customized beauty.
  • Prose Custom Skincare is available for purchase across the United States and Canada on Prose.com.

Roquette Announces Strategic Investment and Innovation Agreement with Beren Therapeutics P.B.C.

Retrieved on: 
Tuesday, May 23, 2023
Biotechnology, Pharmaceutical, Health, Fourth Estate Public Benefit Corporation, Drug development, CMC, Professional corporation, Cyclodextrin, Multimedia, Research, Chemistry, Strategic management, Patient, Ecosystem, Therapy, Pharmaceutical industry, Management, Roquette

Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.

Key Points: 
  • Roquette, a leading provider of pharmaceutical excipients and global leader in plant-based ingredients, is pleased to announce a strategic investment with Beren Therapeutics P.B.C., and the launch of an innovation agreement to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
  • View the full release here: https://www.businesswire.com/news/home/20230523005131/en/
    Beren is a vertically integrated biopharmaceutical company focused on addressing the world’s most significant health challenges.
  • Roquette recognizes the revolutionary potential of Beren’s research to transform the market and the lives of millions of patients worldwide.
  • To learn more about Roquette’s latest strategic partnerships and its wider cyclodextrins portfolio, visit: www.roquette.com .

NOVOS Debuts Longevity Product Line, Leveraging Breakthrough Scientific Discoveries to Slow Down the Pace of Aging

Retrieved on: 
Wednesday, May 10, 2023
Health, Other Health, General Health, Research, Vitamins, Supplements, Science, Acceleration, Cognition, Fourth Estate Public Benefit Corporation, DNA, Drink, NAD, Doctor of Philosophy, PBC, Professional corporation, Ageing, NMN, Multimedia, MIT, Life expectancy, Calcium alpha-ketoglutarate, Harvard Medical School, Cellular senescence, Capsule, Salk Institute for Biological Studies, DNA repair, Metabolism, Mortality, Longevity, Glycine, Pharmaceutical industry, Dietary supplement, NOVOS

After four years of rigorous testing and formulating, NOVOS is now unveiling its line of science-backed, patent-pending supplements for consumers that aim to slow down the pace of aging by targeting its root causes.

Key Points: 
  • After four years of rigorous testing and formulating, NOVOS is now unveiling its line of science-backed, patent-pending supplements for consumers that aim to slow down the pace of aging by targeting its root causes.
  • The company has gone through multiple third-party research studies to assess the impact of its supplements on longevity and healthy aging.
  • In in-vitro human cell studies, NOVOS supplements were shown to reduce DNA damage from irradiation by up to 77% and inhibit cellular senescence.
  • As a Public Benefit Corporation (PBC), NOVOS is committed to educating consumers about healthy living, regularly publishing Ph.D. and M.D.-authored articles

Transparent and fully traceable company, The Fision, launches today and is revolutionizing the apparel industry

Retrieved on: 
Friday, April 21, 2023
Fourth Estate Public Benefit Corporation, Learning, Carbon footprint, Professional corporation, Clothing, Carbon, Sale, Science, Organization, Soil, Environment, Agriculture

NEW YORK, April 21, 2023 /PRNewswire/ -- Today, The Fision announces the launch of its apparel company, a radically transparent and traceable brand. Through conscious awareness and continuous truth sourcing, The Fision aims to disrupt the apparel manufacturing industry using clothing as a vehicle for good, illustrating care for the planet and encouraging a more sustainable future.

Key Points: 
  • The Fision is launching with a selection of cotton T-shirts that minimize its carbon footprint, starting at the soil.
  • All apparel is finished domestically in Los Angeles where it is knitted, finished, cut and sewn.
  • Scanning The Fision's unique dynamic QR code on each garment allows the consumer to follow the transparent journey of each product's creation.
  • From our unique 'Ownership by All' company structure to our radically transparent production practices, we aim to inspire change."

Symbiotic Unveils Innovative Platform to Foster Social Change

Retrieved on: 
Wednesday, April 19, 2023
Fourth Estate Public Benefit Corporation, Organic, SDG, Social impact, Professional corporation, Sustainable Development Goals, Organization, ESG Quant, Climate change, Non-governmental organization, Map, ESG, Behavior, Symbiosis

The company connects motivated buyers looking for sustainability and social impact to sellers that are primed for profit plus purpose.

Key Points: 
  • The company connects motivated buyers looking for sustainability and social impact to sellers that are primed for profit plus purpose.
  • Companies enjoy working with Symbiotic because each time they make a donation, the system brings visibility to their sustainable and philanthropic efforts.
  • Symbiotic simplifies the complex and often difficult process of meeting ESG strategy that takes time, money, and resources by making key connections between sellers and social impact partners.
  • Symbiotic’s Social Impact as a Service platform brings efficiency and purpose to traditional SDG and ESG programs by providing a clear mechanism for meeting stakeholder and investor expectations.

Red Cell Partners Announces $3 Million in Pre-Seed Funding for Psychedelic Company TARA Mind

Retrieved on: 
Thursday, April 13, 2023
Pharmaceutical, Health, Neurology, Mental Health, Red Cell, Partnership, Depression, Icahn School of Medicine at Mount Sinai, Suicide, Integration, Absenteeism, Professional corporation, Health equity, Veteran, Human, Multimedia, Harvard Medical School, Mount Sinai, Doctor of Philosophy, Science, Stanford University School of Medicine, MDD, MD, Post-traumatic stress disorder, Standard of care, Mental, Navy, Traumatic brain injury, Behavioural sciences, PAT, Entrepreneurship, ROI, TRD, Death, Mental health, Society, Fourth Estate Public Benefit Corporation, Safety, Major depressive disorder, Pharmaceutical industry, Nursing, Psychotherapy, Medicine, Trauma, Practitioner, Psychiatry

Red Cell Partners, an incubation firm building and investing in technology-led companies that bring revolutionary advancements to healthcare and national security, has announced $3 million in pre-seed funding for TARA Mind, a mental health company that enables safe and affordable access to psychedelic-assisted therapy (PAT).

Key Points: 
  • Red Cell Partners, an incubation firm building and investing in technology-led companies that bring revolutionary advancements to healthcare and national security, has announced $3 million in pre-seed funding for TARA Mind, a mental health company that enables safe and affordable access to psychedelic-assisted therapy (PAT).
  • The problem is a large and complicated one exacerbated by misaligned incentives, a global pandemic, and deep-rooted stigma surrounding psychedelics and other alternative therapies.
  • “Far too many people are being failed by our country’s outdated approach to mental health care,” said Red Cell CEO and TARA Mind Co-Founder, Grant Verstandig.
  • At TARA Mind, we aren’t being guided by ‘the buzz’ around psychedelics, nor are we chasing a quick profit from lingering loopholes in a post-COVID world.